Plavix In The News

Schering-Plough Corp. has many promising drugs in late testing, three awaiting approval, plus years of patent protection for its key products, unlike most of its competitors, Chief Executive Fred Hassan told analysts Monday.

Sanofi-Aventis Upped To Overweight By Morgan Stanley

Nov. 24 (Bloomberg) -- Sanofi-Aventis SA , France's largest drugmaker, was raised to ``overweight' from ``equal weight' at Morgan Stanley, which said its new chief executive, Chris Viehbacher , was likely to cut research expenses.

Nov. 24 (Bloomberg) -- Schering-Plough Corp. plans to begin selling products in the next four years that may generate more than $7 billion in combined annual revenue, lessening the company’s dependence on embattled cholesterol pills.

Nov. 24 (Bloomberg) -- Sanofi-Aventis SA , France’s largest drugmaker, increased the most in 19 years in Paris trading after Morgan Stanley analysts raised the rating on the stock to “overweight” from “equal weight.”

Schering-Plough Corp. has many promising drugs in late testing, three awaiting approval, plus years of patent protection for its key products, unlike most of its competitors, Chief Executive Fred Hassan told analysts Monday. The drugmaker has three drugs awaiting U.S. approval and nine more in final human testing - including a new type of anticlotting drug that could grab some of blockbuster ..

The news from continental Europe has been unremittingly grim in recent weeks.

On November 6, 2008, the Supreme Court released its decision in Apotex Inc. v. Sanofi-Synthelabo Canada Inc. The primary issue before the court was the validity of selection patents.

Nov. 24 (Bloomberg) -- Sanofi-Aventis SA , France’s largest drugmaker, increased the most in five weeks in Paris trading after Morgan Stanley analysts raised the rating on the stock to “overweight” from “equal weight.”

STOCKS NEWS Reuters Results diary Stocks on the move Real-time Equity News